New Pharmacoeconomic Analysis Finds KYZATREX® Could Cut the VA’s Total Cost of Testosterone Care by Nearly Half for America’s Veterans
Model projects up to $16.2 million in potential annual savings for every 50,000 veterans transitioned from office-administered injectable therapy —...